• FDA advisory panel voted 8-4 in favor of condoliase for radicular leg pain due to lumbar disc herniation, highlighting its potential for patients who have not responded to conservative treatments.
• The panel emphasized the need for a narrow indication, focusing on patients with confirmed nerve root impingement and failure of at least 6 weeks of conservative therapy.
• Concerns were raised regarding potential immune-related adverse events and long-term effects on spinal health, necessitating careful monitoring and further research.
• Condoliase, currently available in Japan, works by reducing disc volume and relieving pressure on the nerve root, offering a non-opioid alternative to surgery for some patients.